ExeGi Pharma Secures License For Well-Studied Probiotic and more

GAITHERSBURG, Md.May 18, 2015 /PRNewswire-USNewswire/ — ExeGi Pharma, a company focused on developing and commercializing live biotherapeutics and probiotic treatments, announced today that it has signed an agreement with Professor Claudio De Simone, MD, PhD, to produce a generic formulation of the probiotic marketed under the name “VSL#3®.”

ExeGi Pharma will commercialize Visbiome™ and Visbiome™ Extra Strength, a generic formulation which will contain the same strains, in the same concentrations and proportions as the product tested and marketed under the brand name VSL#3®. It will be produced using the same manufacturing facility, methods and quality standards as the original product. The Visbiome™ formulation is a medical food that is intended for the dietary management of pouchitis, inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Read More

Theravance Biopharma (TBPH) Will Present Significant TD-5108 Phase 2 Data at DDW 2015

Theravance Biopharma (NASDAQ: TBPH) announced the presentation of positive data from a Phase 2 study of velusetrag (TD-5108), an investigational drug for the treatment of patients with gastroparesis and other gastrointestinal motility disorders, in a “Poster of Distinction” at Digestive Disease Week (DDW) 2015 in Washington, D.C. Presented data showed that all three doses of velusetrag (5, 15 and 30 mg) reduced gastric emptying time (GE t1/2) compared to placebo in patients with either diabetic or idiopathic gastroparesis. Read More

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.